Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study

Lary J. Kilton*, Al B. Benson, Alice Greenberg, Patricia Johnson, Charles Shapiro, Richard Blough, Suzanne French, Linda Weidner

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

We have conducted a phase II trial of fludarabine phosphate for advanced measurable adenocarcinoma of the pancreas. The drug was administered every 4 weeks by a daily-times-5 bolus schedule beginning at 20 mg/m2day. No responses were observed in 20 evaluable patients, 18 of whom were previously untreated. Dose-limiting toxicity was leukopenia, and gastroenterologic side effects were frequent. Life-threatening or fatal renal dysfunction occurred in 3 patients. In this schedule fludarabine phosphate is ineffective against adenocarcinoma of the pancreas and appears to have unpredictable severe renal toxicity.

Original languageEnglish (US)
Pages (from-to)201-204
Number of pages4
JournalInvestigational New Drugs
Volume10
Issue number3
DOIs
StatePublished - Aug 1992

Keywords

  • adenocarcinoma of pancreas
  • fludarabine phosphate
  • phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas - An Illinois Cancer Center study'. Together they form a unique fingerprint.

Cite this